Zymeworks (ZYME) Tops Q1 EPS by 48c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Zymeworks (ZYME) Tops Q1 EPS by 48c

Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results

May 4, 2022 4:15 PM EDT

Last patient enrolled ahead of expectations in pivotal trial evaluating zanidatamab as monotherapy in 2L biliary tract cancers (BTC) Two zanidatamab data presentations at ASCO in June: 1L breast cancer and 1L gastroesophageal adenocarcinoma (GEA) Presented topoisomerase 1 inhibitor (TOPO1i) antibody-drug conjugate (ADC) platform at World ADC London highlighting next-generation ADC capabilities and potential ADC candidates Completed licensing agreement with Atreca utilizing ZymeLink's auristatin-based ADC platform ZW49 continues to progress towards anticipated data... More